Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Biological Chemistry
CRISPR, Casebia link with StrideBio
by Ann M. Thayer
April 24, 2017
| A version of this story appeared in
Volume 95, Issue 17
CRISPR Therapeutics and Casebia Therapeutics are working with StrideBio to find adeno-associated viral (AAV) vectors for in vivo CRISPR/Cas9-based therapies. Casebia is a joint venture between CRISPR Therapeutics and Bayer. StrideBio will use its structure-guided evolution methods to develop AAV vectors with improved tissue specificity and reduced susceptibility to immune responses. Its technology comes from the work of Aravind Asokan at the University of North Carolina, Chapel Hill, and Mavis Agbandje-McKenna at the University of Florida.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X